BIVV

Why Investors Should Stay Long Eli Lilly and Co Stock

By Bret Kenwell, InvestorPlace Contributor
LLY stock had a sudden drop on Jan. 22, but Eli Lilly and Co recovered the bulk of its losses, which means bulls can stay long for the time being.

Bioverativ’s (BIVV) Quant Score Gives it Buy

By Portfolio Grader
Bioverativ Inc (NULL:BIVV) is ranked as a Buy using Louis Navellier's Portfolio Grader stock evaluator, which incorporates his investing methodology. BIVV has been downgraded from a Strong Buy to a Buy in the last week.

Is Sanofi’s Bioverative Inc Buyout Just the Start?

By Dana Blankenhorn, InvestorPlace Contributor
Bioverativ and Juno Therapeutics both drew buyout bids as drug companies seek to use CAR-T therapy against cancer profitably.

Bioverativ Inc Stock Gets 64% Premium in Acquisition by Sanofi

By InvestorPlace Staff
Bioverativ (BIVV) is being acquired for $11.6 billion in cash. That puts a 64% premium on BIVV stock and signal a new phase in biotech M&A.

5 Stocks the Top-Performing Fund Managers Love

By Harriet Lefton, Writer, TipRanks
Here are five top stocks from the top-performing hedge fund managers so you can follow the "smart money."

5 Top Stock Picks by the Market’s Top Fund Managers

By Harriet Lefton, Writer, TipRanks
Here are five stock picks with particularly bullish hedge fund sentiment, based on recent increases in "smart money" holdings.

It’s a Scratch, Not a Ding for Biogen Inc (BIIB) Stock

By Chris Tyler, InvestorPlace Contributor
It hasn’t been a value-add just yet for Biogen stock, but a spin-off of Bioverativ, should unlock plenty of value for both businesses.